Abpro to become publicly traded via merger with atlantic coastal acquisition corp. ii

Woburn, mass. & new york--(business wire)--abpro corporation (“abpro”), a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with next-generation antibody therapies, and atlantic coastal acquisition corp. ii (nasdaq: acab), a special purpose acquisition corporation (“atlantic costal”), today announced a term sheet to enter into a definitive business combination, which was entered into on september 18, 2023. the transaction is expec.
ACAB Ratings Summary
ACAB Quant Ranking